Part 5/8:
Trade agreements notably stabilize import prices and reduce tariff-related uncertainty for European suppliers. Conversely, countries such as India and Switzerland, which manufacture significant volumes primarily for lower-cost API (Active Pharmaceutical Ingredient) components rather than finished drugs, may see different tariff impacts. Since these imports generally consist of raw materials and intermediates, the likelihood and impact of tariffs are comparatively less severe for finished goods.